Jpmorgan Chase & CO Matinas Bio Pharma Holdings, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Matinas Bio Pharma Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 45,589 shares of MTNB stock, worth $25,985. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,589
Previous 45,501
0.19%
Holding current value
$25,985
Previous $12,000
41.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MTNB
# of Institutions
32Shares Held
36.9MCall Options Held
0Put Options Held
0-
Highbridge Capital Management LLC New York, NY10.6MShares$6.07 Million0.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.32MShares$5.31 Million0.0% of portfolio
-
Sargent Investment Group, LLC3.49MShares$1.99 Million0.12% of portfolio
-
Black Rock Inc. New York, NY2.48MShares$1.41 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.29MShares$1.31 Million0.0% of portfolio
About Matinas BioPharma Holdings, Inc.
- Ticker MTNB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,864,992
- Market Cap $124M
- Description
- Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic ...